Daily non-political popular news in brief.
New therapeutic targets in the treatment of ulcerative colitis
11-13-2007 · EurekAlert!The morbidity of ulcerative colitis, a chronic inflammatory disease of the colon with unclear etiology and pathogenesis, is a common disease in Europe and has been increasing in China. A research team in China has found that ulcerative colitis is closely related to the over expression of matrix metolloproteinas-1 (MMP-1) and tumor necrosis factor-alpha (TNF-alpha). This finding may bring about new ways to deal with this difficult-to-treat disease.
Read more »
Keywords: therapeutic, targets, treatment, ulcerative, colitis, target, coliti
« Previous | Next »
Similar news on "New therapeutic targets in the treatment of ulcerative colitis":
- Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
10-25-2007 · EurekAlert!
Although many drugs have been used in the treatment of inflammatory bowel disease, none have yet been shown to modify the natural history of the diseases or to maintain a stable remission over time. The introduction of biological agents in the therapeutic armamentarium for Crohn's disease and ulcerative colitis has significantly changed the treatment strategies and outcomes of patients. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients for long-term maintenance of clinical remission.
Similar news · Read more »
- New therapeutic target for treatment of multiple sclerosis
01-22-2008 · EurekAlert!
An international research team, led by a scientist from the Centre hospitalier de l'Université de Montréal, has identified new therapeutic targets for the treatment of multiple sclerosis. In the February issue of Nature Immunology, the team provides fresh answers concerning the role of novel adhesion molecules in the pathogenesis of MS, a chronic autoimmune disease of the nervous system that affects approximately 55,000 young adults in Canada.
Similar news · Read more »
- Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
10-23-2006 · EurekAlert!
Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
Similar news · Read more »
- Potential New Target For Leukemia Treatment
10-10-2006 · ScienceDaily
Cincinnati Children's Hospital Medical Center researchers have identified the crucial role and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. The findings suggest that RhoH GTPase may provide a target for therapeutic intervention in some types of leukemia. The paper is due to appear in an upcoming edition of the journal, Nature Immunology.
Similar news · Read more »
- Genes set scene for metastasis
04-11-2007 · EurekAlert!
Biologists at Memorial Sloan-Kettering Cancer Center have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor. These genes were also found to promote the spread of breast cancer to the lungs. The study, conducted in mice and reported in this week's Nature, helps to explain how cancer metastasis can occur and highlights targets for therapeutic treatment.
Similar news · Read more »
- New gene found for Crohn's disease
10-26-2006 · EurekAlert!
A new gene associated with Crohn's disease has been identified by a team of researchers. Interestingly, one of the mutations in the gene, which codes for a receptor in a major inflammatory pathway, appears to confer significant protection against the disease. The finding, the researchers report, points to a crucial target for drugs that might better manage both Crohn's and ulcerative colitis, which affect more than one million Americans.
Similar news · Read more »
- Scientists find major susceptibility gene for Crohn's disease
10-26-2006 · EurekAlert!
Researchers report the discovery of a new genetic link to Crohn's disease. Mutations of a gene, which codes for a receptor in a major inflammatory pathway, are strongly associated with Crohn's, they found. Surprisingly, one type of mutation appears to confer significant protection, prioritizing a crucial target for drugs that might better manage Crohn's disease and ulcerative colitis. More than 1 million Americans have Crohn's or colitis, known collectively as inflammatory bowel disease.
Similar news · Read more »
- Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment
04-18-2007 · EurekAlert!
Researchers at the University of Pennsylvania School of Medicine have discovered that an enzyme produced by lung-infecting bacteria further shuts down a protein that is defective in cystic fibrosis patients. The disruption to this protein that conveys ions from lung cells to airways causes thick mucus to buildup inside the lung. The finding suggests a new therapeutic target for treating lung infections in some cystic fibrosis patients.
Similar news · Read more »
- Giving asthma T(he)SL(i)P by blocking OX40
12-03-2007 · EurekAlert!
Inflammatory disorders such as asthma and eczema are overzealous immune responses by the body to otherwise innocuous environmental conditions. The protein TSLP is a potent activator of the allergic inflammatory response, and a new report has identified a role for another protein, OX40, in TSLP-induced allergic reactions in mice and monkeys. These data point to the interaction between OX40 and its partner protein, OX40L, as a promising therapeutic target for the treatment of allergic diseases.
Similar news · Read more »
- Scientists find gene target that may protect against Crohn's disease and ulcerative colitis
10-26-2006 · EurekAlert!
According to one of the Canadian principal investigators, director of the Laboratory in Genetics and Genomic Medicine of Inflammation at the Montreal Heart Institute, Dr. John D. Rioux, "This discovery may lead to a paradigm shift in our thinking from 'genetics of diseases to genetics of health,' particularly as concerns Crohn's disease and ulcerative colitis."
Similar news · Read more »
